Ctrl

K

Cenegermin

Class
Cytokines
Subclass
Polypeptides
Substance name
Cenegermin
Brand names
Oxervate®
Common formulations
Ophthalmic solution
Dosage and administration
Adults patients
Treatment of neurotrophic keratitis
•
0.002% OPHTH q2h for 6 times a day for 8 weeks
Indications for use
Labeled indications
Adults
•
Treatment of neurotrophic keratitis
Children
•
Treatment of neurotrophic keratitis
Pregnancy and breastfeeding
Breastfeeding
Unlikely to have adverse effects in breastfed infants.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource